Figure 4.

HER2 expression level is correlated with paclitaxel treatment efficacy in three human breast cancer xenograft mouse models. (a) Representative [⁸⁹Zr]-pertuzumab PET images of BT474, MDA-MB-361, and MDA-MB-231 tumors are shown as a transverse cross-section through the mouse. Red arrows denote tumors. (b) Representative [¹⁸F]-FDG PET images of BT474, MDA-MB-361, and MDA-MB-231 tumors from day zero to day six in transverse section. Red arrows denote tumors. (c) SUV_mean of [¹⁸F]-FDG in BT474, MDA-MB-361, and MDA-MB-231 tumors from day zero to day six. Mixed ANOVA and Tukey’s post hoc test: ns, non-significant; * p < 0.05. (d) The percent change of SUV_mean of [¹⁸F]-FDG from day three to day six is negatively correlated with SUV_mean of [⁸⁹Zr]-pertuzumab. Spearman’s correlation: r = −0.5887, p = 0.0030. (e) High HER2 (SUV_mean $\ge$ 2.4) tumors show a more reduced SUV_mean of [¹⁸F]-FDG from day zero to day six than low HER2 (SUV_mean < 2.4) tumors. Unpaired t-test: p < 0.001.